On April 18, 2024, a high-profile delegation led by Xu Feng, Secretary of Shanghai Municipal Party Committee for Science and Technology, descended upon Shanghai Vitalgen BioPharma Co., Ltd. (hereinafter referred to as “Vitalgen” or the “Company”). Accompanying Xu Feng were Meng Xing, the Director of the Office of Secretary of Shanghai Municipal Party Committee for Science and Technology, and Dong Liangyan, Deputy Director of the Biotechnology and Pharmaceutical Department of Science and Technology Commission of Shanghai Municipality.

Dr. Zhao Xiaoping, Chairman and General Manager of Vitalgen, warmly welcomed Secretary Xu Feng and expressed heartfelt gratitude for the unwavering support and attention shown by the Shanghai Municipal Party Committee for Science and Technology and the Science and Technology Commission of Shanghai Municipality. Dr. Zhao proceeded to provide an overview of the company’s endeavors, research advancements, and future plans. Secretary Xu Feng lauded the company’s groundbreaking innovations and eagerly inquired about the challenges and needs encountered during its growth trajectory. With utmost diligence, he attentively absorbed the company’s recommendations pertaining to Shanghai’s foray into the burgeoning field of gene therapy. Secretary Xu Feng assured that the Science and Technology Commission of Shanghai Municipality would continue to offer robust support for the company’s technological breakthroughs in the core domain of gene therapy, fostering a nurturing ecosystem for its development. He further urged the company to maintain unwavering confidence and wholeheartedly propel the building of technological platforms and research pipelines, with the ultimate aim of expediting the availability of these transformative technologies to patients.

As an indigenous Shanghai enterprise firmly rooted in the scientific enclave of Zhangjiang Science City, with production facilities established in the Lingang Blue Bay and the Waigaoqiao Free Trade Zone, the company remains committed to harnessing scientific talents and industry resources, bolstering the fusion of academia, research, and medicine, and spearheading the gene therapy arena. By doing so, it endeavors to contribute significantly to Shanghai’s vision of becoming a globally competitive hub for scientific and technological innovation while achieving self-sufficiency at the forefront of advanced research.